Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Feb 14, 2022
Revive Therapeutics To Expedite Patient Enrollments For Phase 3 COVID Oral Therapeutic Trial Jan 5, 2022
Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3… Dec 3, 2021
Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion… Nov 23, 2021
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection… Nov 16, 2021
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin… Nov 3, 2021
Clinical Trial Manager Remains Upbeat Following Bucillamine’s Latest Successful Showing With The DSMB Nov 1, 2021